Were the GYRE share sales by the COO executed as a single trade or multiple trades?

The sales were executed in multiple trades, with a weighted average price of $6.17 per share. Individual trades occurred at prices ranging from $6.16 to $6.18, according to the Form 4 footnote.

Gyre Therapeutics (GYRE) COO sells 2,800 shares after exercising options

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

GYRE THERAPEUTICS, INC. Chief Operating Officer Ye Weiguo reported a same‑day option exercise and share sale. He exercised options to acquire 2,800 shares of common stock at an exercise price of $0.75 per share, then sold 2,800 shares in an open‑market transaction at a weighted average price of $6.17 per share.

After these transactions, Ye directly holds 700,000 shares of common stock. The exercised options covered 2,800 shares of common stock originally granted as a stock option (right to buy) that was fully vested.

Insider Trade Summary

Net Seller: 2,800 shares ($17,276)

Net Sell 3 txns

Insider Ye Weiguo

Role Chief Operating Officer

Sold 2,800 shs ($17K)

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	2,800	$0.00	--
Exercise	Common Stock	2,800	$0.75	$2K
Sale	Common Stock	2,800	$6.17	$17K

Holdings After Transaction: Stock Option (Right to Buy) — 838,701 shares (Direct, null); Common Stock — 702,800 shares (Direct, null)

Footnotes (1)

The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $6.16 to $6.18. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. These options are vested in full.

Key Figures

Shares sold: 2,800 shares Sale price: $6.17 per share Shares exercised: 2,800 shares +3 more

6 metrics

Shares sold 2,800 shares Common Stock sold in open-market transaction

Sale price $6.17 per share Weighted average sale price; trades from $6.16 to $6.18

Shares exercised 2,800 shares Common Stock acquired via option exercise

Option exercise price $0.75 per share Stock Option (Right to Buy) exercise price

Shares held after transaction 700,000 shares Direct common stock ownership after transactions

Option expiration 2030-10-31 Expiration date of exercised stock option grant

Key Terms

open-market sale, derivative exercise/conversion, Stock Option (Right to Buy), weighted average sale price

4 terms

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

derivative exercise/conversion financial

"transaction_action": "derivative exercise/conversion""

Stock Option (Right to Buy) financial

"security_title": "Stock Option (Right to Buy)""

weighted average sale price financial

"The price reported represents the weighted average sale price per share."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/15/2026 - 04:01 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ye Weiguo

(Last)

(First)

(Middle)

C/O GYRE THERAPEUTICS, INC.

12730 HIGH BLUFF DRIVE, SUITE 250

(Street)

SAN DIEGO

CALIFORNIA

92130

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
GYRE THERAPEUTICS, INC. [ GYRE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Operating Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/11/2026		M		2,800	A	$0.75	702,800	D
Common Stock	06/11/2026		S		2,800	D	$6.17⁽¹⁾	700,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$0.75	06/11/2026		M			2,800	⁽²⁾	10/31/2030	Common Stock	2,800	$0	838,701	D

Explanation of Responses:

1. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $6.16 to $6.18. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

2. These options are vested in full.

	/s/ Weiguo Ye	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did GYRE COO Ye Weiguo report on this Form 4?

COO Ye Weiguo reported exercising options for 2,800 Gyre Therapeutics shares and then selling 2,800 shares in an open‑market transaction. These transactions occurred on the same date and involved the company’s common stock.

How many GYRE shares did the COO sell and at what price?

He sold 2,800 shares of Gyre Therapeutics common stock at a weighted average price of $6.17 per share. The sales took place in multiple trades with prices ranging from $6.16 to $6.18 per share.

What stock options did the GYRE COO exercise in this filing?

He exercised stock options covering 2,800 shares of Gyre Therapeutics common stock at an exercise price of $0.75 per share. The filing notes these options were fully vested at the time of exercise.

How many GYRE shares does COO Ye Weiguo hold after these transactions?

Following the option exercise and sale of shares, COO Ye Weiguo directly holds 700,000 shares of Gyre Therapeutics common stock. This post‑transaction balance reflects his remaining direct ownership position reported in the filing.